Platelets: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Rita Xu and Version 1 by Cristina Banfi.

Recent advances in proteomic studies provided additional important information concerning the platelet biology and their response to several pathophysiological pathways. Platelets indeed are a heterogeneous small anucleate blood cell population with a central role both in physiological haemostasis and in pathological states, spanning from thrombosis to inflammation, and cancer. 

Herein, a critical overview is provided on principal platelet proteomic studies focused on platelet biology from signalling to granules content, platelet proteome changes in several diseases, and the impact of drugs on platelet functions. Targeted quantification methods by means of mass spectrometry might be employed for more precise, robust and accurate quantification of selected proteins, which might be used as biomarkers for disease diagnosis, prognosis and therapy, and their strong clinical impact in the near future.

  • platelets
  • proteomics
  • mass spectrometry
Please wait, diff process is still running!

References

  1. Machlus, K.R.; Italiano, J.E. 2—Megakaryocyte Development and Platelet Formation. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 25–46.
  2. Lefrancais, E.; Ortiz-Munoz, G.; Caudrillier, A.; Mallavia, B.; Liu, F.; Sayah, D.M.; Thornton, E.E.; Headley, M.B.; David, T.; Coughlin, S.R.; et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017, 544, 105–109.
  3. van der Meijden, P.E.J.; Heemskerk, J.W.M. Platelet biology and functions: New concepts and clinical perspectives. Nat. Rev. Cardiol. 2019, 16, 166–179.
  4. Semple, J.W.; Italiano, J.E., Jr.; Freedman, J. Platelets and the immune continuum. Nat. Rev. Immunol. 2011, 11, 264–274.
  5. von Hundelshausen, P.; Weber, C. Platelets as immune cells: Bridging inflammation and cardiovascular disease. Circ. Res. 2007, 100, 27–40.
  6. Clemetson, K.J.; Clemetson, J.M. 9—Platelet Receptors. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 169–192.
  7. Flaumenhaft, R.; Sharda, A. 19—Platelet Secretion. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 349–370.
  8. O’Donnell, V.B.; Murphy, R.C.; Watson, S.P. Platelet lipidomics: Modern day perspective on lipid discovery and characterization in platelets. Circ. Res. 2014, 114, 1185–1203.
  9. Gasecka, A.; Nieuwland, R.; Siljander, P.R.M. 22—Platelet-Derived Extracellular Vesicles. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 401–416.
  10. Provost, P. 6—Platelet MicroRNAs. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 127–138.
  11. Jobe, S. Platelet Heterogeneity. In Platelets in Thrombotic and Non-Thrombotic Disorders; Gresele, P., Kleiman, N.S., Lopez, J., Page, C., Eds.; Springer: Cham, Switzerland, 2017.
  12. Rowley, J.W.; Manne, B.K.; Weyrich, A.S. The Platelet Transcriptome: Coding RNAs. In Platelets in Thrombotic and Non-Thrombotic Disorders; Gresele, P., Kleiman, N.S., Lopez, J., Page, C., Eds.; Springer: Cham, Switzerland, 2017.
  13. Rowley, J.W.; Weyrich, A.S.; Bray, P.F. 7—The Platelet Transcriptome in Health and Disease. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 139–153.
  14. McManus, D.D.; Freedman, J.E. MicroRNAs in platelet function and cardiovascular disease. Nat. Rev. Cardiol. 2015, 12, 711–717.
  15. Fisher, M.H.; Di Paola, J. Genomics and transcriptomics of megakaryocytes and platelets: Implications for health and disease. Res. Pract. Thromb. Haemost. 2018, 2, 630–639.
  16. Nurden, A.T.; Nurden, P. Inherited disorders of platelet function: Selected updates. J. Thromb. Haemost. JTH 2015, 13 (Suppl. 1), S2–S9.
  17. Freson, K. 8—The Platelet Proteome. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 155–167.
  18. Loosse, C.; Swieringa, F.; Heemskerk, J.W.M.; Sickmann, A.; Lorenz, C. Platelet proteomics: From discovery to diagnosis. Expert Rev. Proteom. 2018, 15, 467–476.
  19. Izquierdo, I.; Garcia, A. Platelet proteomics applied to the search for novel antiplatelet therapeutic targets. Expert Rev. Proteom. 2016, 13, 993–1006.
  20. Sharda, A.; Flaumenhaft, R. The life cycle of platelet granules. F1000Research 2018, 7, 236.
  21. Yun, S.H.; Sim, E.H.; Goh, R.Y.; Park, J.I.; Han, J.Y. Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed Res. Int. 2016, 2016, 9060143.
  22. Ozaki, Y.; Suzuki-Inoue, K.; Inoue, O. Platelet receptors activated via mulitmerization: Glycoprotein VI, GPIb-IX-V, and CLEC-2. J. Thromb. Haemost. JTH 2013, 11 (Suppl. 1), 330–339.
  23. Gurbel, P.A.; Kuliopulos, A.; Tantry, U.S. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 500–512.
  24. Sidhu, T.S.; French, S.L.; Hamilton, J.R. Differential signaling by protease-activated receptors: Implications for therapeutic targeting. Int. J. Mol. Sci. 2014, 15, 6169–6183.
  25. Thomas, M.R.; Storey, R.F. The role of platelets in inflammation. Thromb. Haemost. 2015, 114, 449–458.
  26. Lievens, D.; von Hundelshausen, P. Platelets in atherosclerosis. Thromb. Haemost. 2011, 106, 827–838.
  27. Aloui, C.; Prigent, A.; Sut, C.; Tariket, S.; Hamzeh-Cognasse, H.; Pozzetto, B.; Richard, Y.; Cognasse, F.; Laradi, S.; Garraud, O. The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int. J. Mol. Sci. 2014, 15, 22342–22364.
  28. Pamukcu, B.; Lip, G.Y.; Snezhitskiy, V.; Shantsila, E. The CD40-CD40L system in cardiovascular disease. Ann. Med. 2011, 43, 331–340.
  29. Antoniades, C.; Bakogiannis, C.; Tousoulis, D.; Antonopoulos, A.S.; Stefanadis, C. The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J. Am. Coll. Cardiol. 2009, 54, 669–677.
  30. Lord, M.S.; Cheng, B.; Farrugia, B.L.; McCarthy, S.; Whitelock, J.M. Platelet Factor 4 Binds to Vascular Proteoglycans and Controls Both Growth Factor Activities and Platelet Activation. J. Biol. Chem. 2017, 292, 4054–4063.
  31. Woller, G.; Brandt, E.; Mittelstadt, J.; Rybakowski, C.; Petersen, F. Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J. Leukoc. Biol. 2008, 83, 936–945.
  32. Virani, S.S.; Nambi, V.; Hoogeveen, R.; Wasserman, B.A.; Coresh, J.; Gonzalez, F., 2nd; Chambless, L.E.; Mosley, T.H.; Boerwinkle, E.; Ballantyne, C.M. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: The Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur. Heart J. 2011, 32, 459–468.
  33. von Hundelshausen, P.; Koenen, R.R.; Sack, M.; Mause, S.F.; Adriaens, W.; Proudfoot, A.E.; Hackeng, T.M.; Weber, C. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005, 105, 924–930.
  34. Kim, S.J.; Jenne, C.N. Role of platelets in neutrophil extracellular trap (NET) production and tissue injury. Semin. Immunol. 2016, 28, 546–554.
  35. Thalin, C.; Hisada, Y.; Lundstrom, S.; Mackman, N.; Wallen, H. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1724–1738.
  36. Thon, J.N.; Peters, C.G.; Machlus, K.R.; Aslam, R.; Rowley, J.; Macleod, H.; Devine, M.T.; Fuchs, T.A.; Weyrich, A.S.; Semple, J.W.; et al. T granules in human platelets function in TLR9 organization and signaling. J. Cell Biol. 2012, 198, 561–574.
  37. Blair, P.; Flaumenhaft, R. Platelet alpha-granules: Basic biology and clinical correlates. Blood Rev. 2009, 23, 177–189.
  38. Chen, Y.; Yuan, Y.; Li, W. Sorting machineries: How platelet-dense granules differ from alpha-granules. Biosci. Rep. 2018, 38.
  39. Heijnen, H.; van der Sluijs, P. Platelet secretory behaviour: As diverse as the granules . or not? J. Thromb. Haemost. JTH 2015, 13, 2141–2151.
  40. Gremmel, T.; Ay, C.; Riedl, J.; Kopp, C.W.; Eichelberger, B.; Koppensteiner, R.; Panzer, S. Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thromb. Haemost. 2016, 115, 615–621.
  41. Czepluch, F.S.; Kuschicke, H.; Dellas, C.; Riggert, J.; Hasenfuss, G.; Schafer, K. Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease. J. Intern. Med. 2014, 275, 144–154.
  42. Loguinova, M.; Pinegina, N.; Kogan, V.; Vagida, M.; Arakelyan, A.; Shpektor, A.; Margolis, L.; Vasilieva, E. Monocytes of Different Subsets in Complexes with Platelets in Patients with Myocardial Infarction. Thromb. Haemost. 2018, 118, 1969–1981.
  43. Italiano, J.E., Jr.; Mairuhu, A.T.; Flaumenhaft, R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr. Opin. Hematol. 2010, 17, 578–584.
  44. Varon, D.; Shai, E. Platelets and their microparticles as key players in pathophysiological responses. J. Thromb. Haemost. JTH 2015, 13 (Suppl. 1), S40–S46.
  45. Wang, Z.T.; Wang, Z.; Hu, Y.W. Possible roles of platelet-derived microparticles in atherosclerosis. Atherosclerosis 2016, 248, 10–16.
  46. Bao, H.; Chen, Y.X.; Huang, K.; Zhuang, F.; Bao, M.; Han, Y.; Chen, X.H.; Shi, Q.; Yao, Q.P.; Qi, Y.X. Platelet-derived microparticles promote endothelial cell proliferation in hypertension via miR-142-3p. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2018, 32, 3912–3923.
  47. Mezouar, S.; Mege, D.; Darbousset, R.; Farge, D.; Debourdeau, P.; Dignat-George, F.; Panicot-Dubois, L.; Dubois, C. Involvement of platelet-derived microparticles in tumor progression and thrombosis. Semin. Oncol. 2014, 41, 346–358.
  48. El-Gamal, H.; Parray, A.S.; Mir, F.A.; Shuaib, A.; Agouni, A. Circulating microparticles as biomarkers of stroke: A focus on the value of endothelial- and platelet-derived microparticles. J. Cell. Physiol. 2019, 234, 16739–16754.
  49. Wang, N.; Tall, A.R. Cholesterol in platelet biogenesis and activation. Blood 2016, 127, 1949–1953.
  50. Vinik, A.I.; Erbas, T.; Park, T.S.; Nolan, R.; Pittenger, G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001, 24, 1476–1485.
  51. Santilli, F.; Davi, G.; Consoli, A.; Cipollone, F.; Mezzetti, A.; Falco, A.; Taraborelli, T.; Devangelio, E.; Ciabattoni, G.; Basili, S.; et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2006, 47, 391–397.
  52. Gkaliagkousi, E.; Passacquale, G.; Douma, S.; Zamboulis, C.; Ferro, A. Platelet activation in essential hypertension: Implications for antiplatelet treatment. Am. J. Hypertens. 2010, 23, 229–236.
  53. Badimon, L.; Bugiardini, R.; Cenko, E.; Cubedo, J.; Dorobantu, M.; Duncker, D.J.; Estruch, R.; Milicic, D.; Tousoulis, D.; Vasiljevic, Z.; et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: Obesity and heart disease. Eur. Heart J. 2017, 38, 1951–1958.
  54. Harding, S.A.; Sarma, J.; Josephs, D.H.; Cruden, N.L.; Din, J.N.; Twomey, P.J.; Fox, K.A.; Newby, D.E. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004, 109, 1926–1929.
  55. Csordas, A.; Bernhard, D. The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev. Cardiol. 2013, 10, 219–230.
  56. Scherlinger, M.; Guillotin, V.; Truchetet, M.E.; Contin-Bordes, C.; Sisirak, V.; Duffau, P.; Lazaro, E.; Richez, C.; Blanco, P. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmun. Rev. 2018, 17, 625–635.
  57. Baaten, C.; Ten Cate, H.; van der Meijden, P.E.J.; Heemskerk, J.W.M. Platelet populations and priming in hematological diseases. Blood Rev. 2017, 31, 389–399.
  58. Spronk, H.M.H.; Padro, T.; Siland, J.E.; Prochaska, J.H.; Winters, J.; van der Wal, A.C.; Posthuma, J.J.; Lowe, G.; D’Alessandro, E.; Wenzel, P.; et al. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. Thromb. Haemost. 2018, 118, 229–250.
  59. Michelson, A.D.; Cattaneo, M.; Frelinger, A.; Newman, P. Platelets (Fourth Edition), 4th ed.; Academic Press: Cambridge, MA, USA; Elsevier Inc.: Amsterdam, The Netherlands, 2019.
  60. Davi, G.; Patrono, C. Platelet activation and atherothrombosis. New Engl. J. Med. 2007, 357, 2482–2494.
  61. Gawaz, M.; Borst, O. 26—The Role of Platelets in Atherothrombosis. In Platelets (Fourth Edition); Michelson, A.D., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 459–467.
  62. Totani, L.; Evangelista, V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2357–2361.
  63. Finsterbusch, M.; Schrottmaier, W.C.; Kral-Pointner, J.B.; Salzmann, M.; Assinger, A. Measuring and interpreting platelet-leukocyte aggregates. Platelets 2018, 29, 677–685.
  64. Badimon, L.; Padro, T.; Vilahur, G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care 2012, 1, 60–74.
  65. Badimon, L.; Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 2014, 276, 618–632.
  66. Pretorius, E. Platelets as Potent Signaling Entities in Type 2 Diabetes Mellitus. Trends Endocrinol. Metab. TEM 2019, 30, 532–545.
  67. Santilli, F.; Simeone, P.; Liani, R.; Davi, G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat. 2015, 120, 28–39.
  68. Santilli, F.; Simeone, P.; Liani, R.; Davì, G. Platelets and Diabetes. In Platelets in Thrombotic and Non-Thrombotic Disorders; Gresele, P., Kleiman, N.S., Lopez, J., Page, C., Eds.; Springer: Cham, Switzerland, 2017.
  69. Franco, A.T.; Corken, A.; Ware, J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood 2015, 126, 582–588.
  70. Haemmerle, M.; Stone, R.L.; Menter, D.G.; Afshar-Kharghan, V.; Sood, A.K. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 2018, 33, 965–983.
  71. Labelle, M.; Begum, S.; Hynes, R.O. Platelets guide the formation of early metastatic niches. Proc. Natl. Acad. Sci. USA 2014, 111, E3053–E3061.
  72. Xu, X.R.; Yousef, G.M.; Ni, H. Cancer and platelet crosstalk: Opportunities and challenges for aspirin and other antiplatelet agents. Blood 2018, 131, 1777–1789.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback